Zhang Zunwei, Guan Yujia, Han Jiale, Li Mingming, Shi Miao, Deng Hui
Department of Neurology and Neuroscience Center, First Hospital of Jilin University, Changchun, China.
Department of Endocrinology, First Hospital of Jilin University, Changchun, China.
Front Neurol. 2020 Oct 2;11:516211. doi: 10.3389/fneur.2020.516211. eCollection 2020.
To summarize the characteristics of muscle-specific receptor tyrosine kinase antibody-positive myasthenia gravis (MuSK-MG) in Northeast China. We retrospectively collected 183 confirmed MG patients and divided them into three groups based on the type of serum antibodies: MuSK-MG (14 cases), acetylcholine receptor (AChR)-MG (130 cases), and double-seronegative (DSN)-MG (39 cases). The clinical, diagnostic, therapeutic, and prognosis data were analyzed. MuSK antibody was detected in 26.7% of seronegative MG. The mean age of onset in MuSK-MG was 53.2 ± 13.6 years. Fifty percent of MuSK-MG patients with an onset symptom of pure ocular muscle weakness. The time from onset to other muscle groups' involvement and the time from onset to myasthenic crisis had no significant difference among the three groups ( > 0.05). The proportion of Osserman classification I in MuSK-MG group was lower than that in DSN-MG group. The proportion of Osserman classification IV in MuSK-MG group was higher than that in the other two groups. The incidences of other coexisting autoimmune diseases in MuSK-MG group were higher. Prognosis after the treatment of steroid combined with tacrolimus for MuSK-MG was similar to AChR-MG treated with steroid combined with an immunosuppressant agent ( > 0.05). Patients with MuSK-MG in Northeast China have a modestly later onset age and a proportion of patients may have a mild form of the disease with delayed disease progression. We confirmed the existence of a rare ocular MuSK-MG phenotype, a high proportion of coexisting with other autoimmune diseases, and a good response to steroids combined with tacrolimus for our MuSK-MG series.
总结中国东北地区肌肉特异性受体酪氨酸激酶抗体阳性重症肌无力(MuSK-MG)的特征。我们回顾性收集了183例确诊的重症肌无力患者,并根据血清抗体类型将其分为三组:MuSK-MG(14例)、乙酰胆碱受体(AChR)-MG(130例)和双血清阴性(DSN)-MG(39例)。对临床、诊断、治疗及预后数据进行分析。在血清阴性重症肌无力患者中,MuSK抗体检测率为26.7%。MuSK-MG的平均发病年龄为53.2±13.6岁。50%的MuSK-MG患者首发症状为单纯眼肌无力。三组患者从发病到其他肌群受累的时间以及从发病到肌无力危象的时间无显著差异(>0.05)。MuSK-MG组Osserman分级I级的比例低于DSN-MG组。MuSK-MG组Osserman分级IV级的比例高于其他两组。MuSK-MG组其他合并自身免疫性疾病的发生率更高。MuSK-MG采用激素联合他克莫司治疗后的预后与AChR-MG采用激素联合免疫抑制剂治疗相似(>0.05)。中国东北地区的MuSK-MG患者发病年龄稍晚,部分患者可能病情较轻且疾病进展延迟。我们证实了罕见的眼肌型MuSK-MG表型的存在、与其他自身免疫性疾病共存的高比例情况,以及我们的MuSK-MG系列患者对激素联合他克莫司治疗反应良好。